Inovio Pharmaceuticals 报告第一季度亏损 3047 万美元，计划于 2024 年下半年提交 INO-3107 (RRP) 的 BLA 申请，并讨论阶段性进展 Inovio Pharmaceuticals reports Q1 loss of $30.47M, plans BLA filing for INO-3107 (RRP) in H2 2024 and discusses phase

Inovio Pharmaceuticals 报告第一季度亏损 3047 万美元，低于去年同期的 4065 万美元。 Inovio Pharmaceuticals reported a Q1 loss of $30.47M, down from $40.65M in the previous year. 该公司有望在 2024 年下半年为其首款产品 INO-3107 提交生物制品许可申请 (BLA)，用于治疗复发性呼吸道乳头状瘤病 (RRP)。 The company is on track to file a Biologic License Application (BLA) for its first product, INO-3107, treating recurrent respiratory papillomatosis (RRP), in the second half of 2024. 喉癌治疗药物 INO-3112 也正在取得进展，其中正在讨论 3 期试验设计计划。 INO-3112, a throat cancer treatment, is also progressing, with plans for phase 3 trial designs being discussed.